UCB - Perseverance pays off; BIMZELX® approved for plaque psoriasis in US
*Following previous approvals in the EU and Japan, the FDA finally gave BIMZELX® green light for the treatment of moderate-severe plaque psoriasis in the US. The drug will be available from next month onwards.*UCB guides for BIMZELX® global peak sales of EUR 4bn while we currently project BIMZELX® peak sales of close to EUR 3bn with 50% stemming from psoriasis (of which 60% US sales), while still excluding hidradenitis suppurativa. Hence our estimate might still be somewhat conservative. We consider BIMZELX® as a best-in-class anti-IL17 efficacy-wise but highlight the suicidal ideation among other factors in the drug label which couldUCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.